The platform integrates generative chemistry, affinity prediction, physics-based modeling, and active learning from experimental data to advance compounds across potency, BBB penetration, metabolic stability, safety, and synthetic tractability.
A closed-loop design–make–test cycle for CNS-penetrant STING inhibitors.
Deliverables that feed each design cycle and partner collaboration.
SDF/SMILES structures for synthesis prioritization.
Predicted potency, BBB penetration, ADMET, and safety properties.
Chemical modifications connected to experimental binding and activity data.
Docking, molecular dynamics, and binding-energy estimates.
New experimental results integrated into the next design cycle.
Aicardi–Goutières syndrome is a rare pediatric interferonopathy characterized by chronic type I interferon activation and severe neurological involvement.
Zermatt's lead STING inhibitor program is designed to evaluate whether CNS-penetrant STING inhibition can suppress upstream innate immune signaling in disease-relevant models.
Additional preclinical data are available upon request for qualified partners.